Drug
Ctx112
Ctx112: highest development phase Phase 1/2, developed by CRISPR Therapeutics. 4 trial records tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- CRISPR Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| CTX112 NCT05643742 | Phase 1/2 | B-cell Lymphoma |
| CTX112 NCT07549698 | Phase 1/2 | Warm Autoimmune Hemolytic Anemia (WAIHA) |
| CTX112 NCT07804004 | Phase 1/2 | Progressive Multiple Sclerosis (PMS) |
| CTX112 NCT06925542 | Phase 1 | SLE (Systemic Lupus) |
Latest
No recent events.
Follow Ctx112 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.